Savara INC 10-Q quarterly reports

Savara Inc. reported a wider net loss in Q1 2026 due to increased R&D and G&A expenses, alongside an FDA review extension for MOLBREEVI.

Savara Inc. reported increased net losses for Q3 and the nine months ended September 30, 2025, while securing significant post-period funding and planning to resubmit its MOLBREEVI BLA in December 2025 following an FDA Refusal to File.

Savara Inc. reported increased net losses and R&D expenses in Q2 2025, following an FDA Refusal to File letter for its lead drug candidate, MOLBREEVI, with resubmission planned for December 2025.

Savara Inc. finalizes its BLA submission to the FDA for molgramostim and secures a $200 million debt facility with Hercules Capital, while reporting a net loss for Q1 2025.

Savara Inc. saw a significant increase in research and development expenses in the third quarter of 2024, while also progressing towards a Biological License Application submission for its lead drug candidate.

Savara Inc., a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2024, highlighting increased research and development spending and a recent $100 million capital raise.

Savara Inc. reported a net loss of $20.3 million for the first quarter of 2024, driven by increased research and development expenses.